-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1487 Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Clinical Practice (Health Services and Quality), Diseases, Treatment Considerations, Myeloid Malignancies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Yenny Alejandra Moreno Vanegas, MD, BSc1, Suhaib Younis Mohamed El Khatib, MD2*, Brooke Hisrich, M.D.3*, Alexander Coltoff, MD4, Rory M. Shallis, MD5, Anand Ashwin Patel, MD6, Jan Philipp Bewersdorf, MD7, Timothy S. Oh, MD8*, Yasmin Abaza, MD9, Charles Foucar, MD10, Aaron D. Goldberg11, Adam S. Duvall, MD6, Ehab L. Atallah, MD12, Mark R. Litzow, MD13 and Talha Badar, MD14

1Mayo Clinic, Jacksonville, FL
2UC Health Parkview Medical Center, Pueblo, CO
3Medical University of South Carolina, Charleston
4Medical University of South Carolina, Charleston, SC
5Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT
6Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
7Memorial Sloan Kettering Cancer Center, New York, NY
8Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
9Northwestern University, Chicago, IL
10University of New Mexico, Ann Arbor, MI
11Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
12Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
13Division of Hematology, Mayo Clinic, Rochester, MN
14Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL

Background

Acute myeloid leukemia (AML) with TP53 mutation (m) has poor outcomes even in the contemporary era with median overall survival (OS) of 6-9 months. The only factor that has been shown to improve outcomes is allogeneic hematopoietic cell transplantation (allo-HCT) (Badar et al AJH 2022; Leukemia 2023). However, the role of allo-HCT for TP53-m AML continues to be a matter of debate given high rates of relapse after allo-HCT particularly in TP53-m AML with complex cytogenetics (CG). We used the COMMAND consortium database to investigate the factors that influenced physician’s decision for allo-HCT in TP53-m AML.

Method

We conducted a multicenter observational study in collaboration with 7 U.S. academic centers under COMMAND consortium. We reviewed electronic medical records of 369 TP53-m AML patients to analyze reasons for not pursuing allo-HCT including refractory disease, donor availability, advanced age/co-morbidities, physician perspective on ineffectiveness of allo-HCT in improving outcome and patient’s decision. Diagnostic criteria for TP53 allelic state were according to the International Consensus Classification (ICC) (Blood 2022; 140:1200). Next-generation sequencing and cytogenetic studies were performed according to institutional standard protocols.

Results

The median age at diagnosis was 68 years, with 222 (60.5%) patients being male. The majority of patients were diagnosed with de novo AML 179 (48.8%), followed by secondary AML (sAML) in 103 (28%) patients, and therapy-related (t)AML in 85 (23.2%) patients. Ninety-four percent of evaluable patients had complex cytogenetics (CG) and 192 (52%) had multi-hit TP53-m. One-hundred forty-seven (42%) patients received intensive chemotherapy (CPX 351 [66 (44%)], 7+3 [78 (53%)]), while 205 (58%) patients received low-intensity regimens including hypomethylating agents (HMA) plus venetoclax (137 [66%]) and HMA +/- investigational agents (68 [33%]). The rate of complete remission (CR)/CR with incomplete count recovery (CRi) was 34.4% and overall response rate (CR/CRi + partial remission [PR] + morphologic leukemia free state [MLFS]) was 52%. Forty-seven (13%) patients received allo-HCT in CR1 and 17 (5%) patients received allo-HCT in CR2.

Of the 294 patients for whom data on allo-HCT decision-making was available, the most common reason for not proceeding to allo-HCT was refractory disease in 126 (43%) patients. Other significant reasons included advanced age/comorbidities (n=78 [30.6%]), physician recommendation (n=7 [2%]), patient’s decision (n=24 [9.4%]), and patient relocation or changing healthcare providers (n= 9 [3.5%]). Two (0.4%) patients had no suitable donor available for allo-HCT.

Amongst the 7 patients for whom allo-HCT was not pursued due to physician’s decision, the median age of the patients was 69 years (R, 59-70), 3 (25%) patients had sAML, and all of them had multi-hit TP53-m associated with complex CG. Six out of seven (86%) patients received HMA plus venetoclax and 1 (14%) patient received HMA-based induction. Six patients achieved CR/CRi after induction and 1 patient had partial remission. The median survival of these patients was 11 months (R, 10.7-11.3), eventually all patients died from progressive AML.

Conclusion

Our survey suggests that the primary reason for not proceeding with allo-HCT was refractory disease, underlying the difficulty in achieving the disease control needed for allo-HCT. There is an urgent need for better frontline therapies tailored specifically for TP53-m AML, along with refined patient selection criteria to better identify candidates who would benefit most from allo-HCT to potentially improve their long-term outcomes.

Disclosures: Shallis: Gilead Sciences, Inc: Consultancy, Honoraria; Servier: Consultancy, Honoraria, Other: Steering Commitee; Rigel: Consultancy, Honoraria; Kura Oncology: Consultancy, Honoraria. Patel: Pfizer: Research Funding; AbbVie: Honoraria; Bristol Myers Squibb: Honoraria; Sumitomo: Research Funding; Sobi: Honoraria; Kronos Bio: Research Funding. Foucar: Novartis: Research Funding. Goldberg: Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; DAVA Oncology: Honoraria; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celularity: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Ikena Oncology: Consultancy; Syndax Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; AROG: Research Funding; Pfizer: Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kura Oncology: Honoraria, Research Funding; Molecular Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees; Aptose: Research Funding; Aprea: Research Funding. Atallah: Novartis Pharmaceuticals Corporation: Honoraria. Litzow: Abbvie: Research Funding; Amgen: Research Funding, Speakers Bureau; Actinium: Research Funding; Astellas: Research Funding; Pluristem: Research Funding; Sanofi: Research Funding; Beigene: Speakers Bureau; Biosight: Other: Data Safety Monitoring Committee. Badar: Takeda: Other: advisory board ; Morphosys: Other: Advisory Board; pfizer: Other: Advisory board.

*signifies non-member of ASH